Effect of moderate liver impairment on the pharmacokinetics of saquinavir after administration of saquinavir/ritonavir 1000/100mg BID in HIV patients.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Ritonavir; Saquinavir
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by Roche.
- 20 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.